Navigation Links
Gene Therapy for HIV Inches Forward
Date:6/16/2010

Viable treatment is still a long way off, researchers say

WEDNESDAY, June 16 (HealthDay News) -- Researchers report they've moved a step closer to treating HIV patients with gene therapy that could potentially one day keep the AIDS-causing virus at bay.

The study, published in the June 16 issue of the journal Science Translational Medicine, only looked at one step of the gene therapy process, and there's no guarantee that genetically manipulating a patient's own cells will succeed or work better than existing drug therapies.

Still, "we demonstrated that we could make this happen," said study lead author David L. DiGiusto, a biologist and immunologist at City of Hope, a hospital and research center in Duarte, Calif. And the research took place in people, not in test tubes.

Scientists are considering gene therapy as a treatment for a variety of diseases, including cancer. One approach involves inserting engineered genes into the body to change its response to illness.

In the new study, researchers genetically manipulated blood cells to resist HIV and inserted them into four HIV-positive patients who had lymphoma, a blood cancer.

The patients' healthy blood cells had been stored earlier and were being transplanted to treat the lymphoma.

Ideally, the cells would multiply and fight off HIV infection. In that case, "the virus has nowhere to grow, no way to expand in the patient," DiGiusto said.

At this early point in the research process, however, the goal was to see if the implanted cells would survive. They did, remaining in the bloodstreams of the subjects for two years.

In the next phases of research, scientists will try to implant enough genetically engineered cells to actually boost the body's ability to fight off HIV, DiGiusto said.

Plenty of caveats still exist. The research, as DiGiusto said, is experimental. And there's the matter of cost: He estimated that the price for gene therapy treatment for HIV patients could run about as much as a bone marrow transplant. Those cost about $100,000.

On the other hand, gene therapy has the potential to free HIV patients from a lifetime of taking medications that may fail to work, especially if the virus develops immunity to them, said David V. Schaffer, co-director of the Berkeley Stem Cell Center at the University of California at Berkeley and co-author of a commentary accompanying DiGiusto's study.

Over time, the savings on medications could outweigh the cost of the gene therapy, he noted.

The treatment wouldn't necessarily be a cure because the virus would remain in the body. Still, it could create a situation "where HIV is present but at levels that are too low to detect and don't cause AIDS," Schaffer said.

More information

For more about gene therapy, visit the U.S. National Library of Medicine.



SOURCES: David L. DiGiusto, Ph.D., director, Analytical Cytometry Core Facility, City of Hope, Duarte, Calif.; David V. Schaffer, Ph.D., co-director, Berkeley Stem Cell Center, University of California at Berkeley; June 16, 2010, Science Translational Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Gino Tutera, M.D., F.A.C.O.G. Brings SottoPelle Therapy to Middle Tennessee, Opens Practice in Nashville Medical District
2. Combined BRAF-targeted and immunotherapy shows promise for melanoma treatment
3. Longer Antiviral Therapy Reduces Lung Transplant Complications
4. SDI Reports: Roughly Half of Patients Prescribed the Most Popular Osteoporosis Drugs Discontinue Therapy Within 6 Months -- Amgen's Prolia Offers New Dosing Option
5. New promising therapy against systemic sclerosis
6. CPAP therapy provides a memory boost for adults with sleep apnea
7. Updated HIV therapy guidelines would reduce risk of transmission, save lives, billions in costs
8. Experimental targeted therapy shows early promise against medulloblastomas
9. Antibody therapy lengthens survival of metastatic melanoma patients in large clinical trial
10. Targeted Therapy Shows Promise Against Deadly Brain Cancer
11. Ft Myers Plastic Surgeon, Dr. Robert J. Brueck MD, Performs Facial Rejuvenation Using Innovative Stem Cell Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene Therapy for HIV Inches Forward
(Date:2/6/2016)... ... 2016 , ... Research has shown that building shame resilience ... and level of relapse. , At the 2016 iaedp Symposium, the ... the critical tasks of the recovery phase and beyond including relapse prevention and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
(Date:2/5/2016)... City, UT (PRWEB) , ... February 05, 2016 , ... ... Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in ... Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology: